公开(公告)号：US20230138310A1

公开(公告)日：2023-05-04

申请号：US17759807

申请日：2020-03-26

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  FRONTIER BIOTECHNOLOGIES INC.

Inventor： Hong LIU ,  Jian LI ,  Wenhao DAI ,  Jingjing PENG ,  Xiong XIE ,  Shulei HU ,  Chunpu LI ,  Yechun XU ,  Haitao YANG ,  Leike ZHANG ,  Haixia SU ,  Hualiang JIANG ,  Zhenming JIN ,  Gengfu XIAO ,  Kaixian CHEN

IPC: C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D401/12 ,  C07D411/12 ,  C07D471/04 ,  C07D207/12 ,  A61P31/14

Abstract: Use of an aldehyde-based compound as represented by general formula I, a pharmaceutical composition, a pharmaceutical salt, an enantiomer, a diastereomer and a racemic compound thereof as a novel coronavirus 2019 (2019-nCov) 3CL protease inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections, pneumonia and other related diseases caused by the novel coronavirus infection 2019.

公开(公告)号：US20240208954A1

公开(公告)日：2024-06-27

申请号：US18013696

申请日：2021-06-29

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Hong LIU ,  Jiang WANG ,  Cen XIE ,  Yameng LIU ,  Shulei HU ,  Cuina LI ,  Feng GAO ,  Kanglong WANG ,  Yong WANG ,  Xianchun ZHONG ,  Yuqiang SHI ,  Hualiang JIANG ,  Kaixian CHEN

IPC: C07D413/10 ,  A61K31/4245 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/675 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  C07D271/06 ,  C07D413/14 ,  C07F9/6558

CPC classification number: C07D413/10 ,  A61K31/4245 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/675 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  C07D271/06 ,  C07D413/14 ,  C07F9/65583

Abstract: The present invention relates to the fields of pharmaceutical chemistry and pharmacotherapeutics, and in particular to a compound as represented by general formula I, a racemate, an R-isomer, an S-isomer and a pharmaceutically acceptable salt thereof and a mixture of same, a preparation method therefor, a pharmaceutical composition containing the compound and the use thereof as an SIP receptor agonist. The oxadiazole compound involved in the present invention can be used for treating SIP receptor agonist related diseases.

公开(公告)号：US20230133600A1

公开(公告)日：2023-05-04

申请号：US17796076

申请日：2021-01-28

Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Inventor： Hong LIU ,  Jian LI ,  Jingjing PENG ,  Xiong XIE ,  Wenhao DAI ,  Shulei HU ,  Chunpu LI ,  Leike ZHANG ,  Zhenming JIN ,  Yechun XU ,  Gengfu XIAO ,  Haitao YANG ,  Fang BAI ,  Xi CHENG ,  Hualiang JIANG ,  Kaixian CHEN

IPC: A61K31/404 ,  A61K31/4412 ,  A61K31/4025 ,  A61K31/498 ,  A61K31/4709 ,  A61K31/443 ,  A61K31/4545 ,  A61K31/454 ,  A61K31/4535 ,  A61K31/453 ,  A61K31/4525 ,  A61K31/4439 ,  A61K31/437 ,  A61K31/4155

Abstract: A class of ketoamide-based compounds, in particular, a ketoarnide-based compound as represented by general formula A is provided. The ketoamide compound may be used as a 2019 novel coronavirus (2019-nCov) 3 CL protease inhibitor and/or human cathepsin L inhibitor, and/or may be used in the preparation of a medicament for treating and/or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. Pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in the preparation of a medicament for treating and/or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection are also provided.